REIG JOFRE submits press release on the results of the second quarter of 2023

REIG JOFRE grew 19% in revenue and 25% in EBITDA up to the second quarter of 2023.

REIG JOFRE reached 157 million euros of sales, 19% above the first half of 2022. This was made possible by an excellent semester in the Specialty Pharmacare Division and the progressive utilisation of the capacity of the new plant in Barcelona. Profitability was also improved, with EBITDA growth of 25% to reach 17.8 million euros compared to 14.2 million euros in the first half of the previous year.

The Specialty Pharmacare division, focused on the prescription medical product, could close with a remarkable growth in revenue by 31%. The division with the greatest weight in sales, Pharmaceutical Technologies, dedicated to injectable products and antibiotics, achieved a growth of 14%, the same as the Consumer Healthcare division, the consumer products division, under the FORTE PHARMA brand, in the French, Belgian and Spanish markets, as well as Reig Jofre’s OTC products.

REIG JOFRE has just signed an agreement with the EU to reserve capacity for the manufacture of vaccines in the event of a health emergency for 4 years from July 2023.

Descargue el documento completo (PDF)